Arcus biosciences, inc. appoints antoni ribas to its board of directors

Arcus biosciences, inc. announced that antoni ribas, m.d., ph.d. has joined the company’s board of directors. dr. ribas is an internationally recognized physician-scientist who conducts translational and clinical research aimed at understanding how the immune system can be used to treat cancer. he has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered t cells, and braf-targeted therapies. his efforts have been instrumental in transforming the treatment paradigm for oncology patients, particularly those with malignant melanoma, having served as principal investigator for multiple trials, including those involving the breakthrough cancer therapy, keytruda. dr. ribas is professor of medicine, surgery, and molecular and medical pharmacology at the university of california los angeles (ucla), director of the tumor immunology program at the ucla jonsson comprehensive cancer center, and director of the parker institute for cancer immunotherapy center at ucla. he is currently the president-elect for the american association for cancer research (aacr). dr. ribas has founded or advised several successful biopharma companies in addition to arcus, such as kite pharma and flexus biosciences. most recently, he co-founded pact pharma, a company developing personalized cancer neoantigen-targeted t cell therapies, together with professors david baltimore and jim heath and arcus co-founders, terry rosen and juan jaen. dr. ribas has been a member of the arcus scientific advisory board since its creation in 2015.
RCUS Ratings Summary
RCUS Quant Ranking